Curaleaf (OTCMKTS:CURLF) Releases Quarterly Earnings Results, Beats Expectations By $0.25 EPS

Curaleaf (OTCMKTS:CURLF) released its quarterly earnings data on Wednesday. The company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.20) by $0.25, Zacks reports. Curaleaf had a negative return on equity of 8.11% and a negative net margin of 7.76%.

Curaleaf Stock Performance

OTCMKTS CURLF traded down $0.66 during trading hours on Wednesday, hitting $8.35. 153,036 shares of the company’s stock traded hands, compared to its average volume of 314,353. The business’s fifty day moving average price is $7.07 and its two-hundred day moving average price is $7.68. The company has a current ratio of 1.56, a quick ratio of 0.74 and a debt-to-equity ratio of 1.05. The firm has a market capitalization of $1.95 billion, a P/E ratio of -21.41 and a beta of 1.56. Curaleaf has a 52 week low of $4.56 and a 52 week high of $15.15.

Wall Street Analyst Weigh In

Separately, Zacks Research raised shares of Curaleaf from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 14th. Three research analysts have rated the stock with a Strong Buy rating and one has given a Buy rating to the stock. According to data from MarketBeat, Curaleaf presently has an average rating of “Strong Buy”.

About Curaleaf

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.